Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

ABSTRACT:

Background

Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes far longer, and the interpretation of biomarker findings is particular relevant for individuals who present at a memory clinic, but are deemed cognitively normal. The objective of the current study is to construct biomarker-based prognostic models for personalized risk of clinical progression in cognitively normal individuals presenting at a memory clinic.

Methods

We included 481 individuals with subjective cognitive decline (SCD) from the Amsterdam Dementia Cohort. Prognostic models were developed by Cox regression with patient characteristics, MRI, and/or

SUBMITTER: van Maurik IS 

PROVIDER: S-EPMC6466790 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature